Common Stock, $0.0001 par value
- Symbol
- YARW
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Yarrow Bioscience, Inc.
YARWNASDAQEQUITYCurrent
Other Events
Item 8.01. Other Events. Corporate Presentation On September 10, 2026, Yarrow Bioscience, Inc., a Delaware corporation (the “Company”), made available the Company’s investor presentation to be used in general corporate communications and investor communications. A copy of the corporate presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.…
Company context
Yarrow Bioscience, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company is developing YB-101, a potentially first-in-class anti-thyroid stimulating hormone receptor (“TSHR”) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both GD and TED. For more information, visit www.yarrowbioscience.com.
Current securities
Historical securities (1)
Registered securities in this filing
Yarrow Bioscience, Inc. · 8-K · Filed 2026-09-10
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events.
Corporate Presentation
On September 10, 2026, Yarrow Bioscience, Inc., a
Delaware corporation (the “Company”), made available the Company’s investor presentation to be used in general corporate
communications and investor communications. A copy of the corporate presentation is filed as Exhibit 99.1 to this Current Report
on Form 8-K and is incorporated by reference herein.
Update to Part I, Item 1 - Business of the Annual
Report
This Current Report on Form 8-K updates Part I, Item
1 - Business of the Annual Report on Form 10-K for the year ended December 31, 2025 (the “Annual Report”)
of the Company to reflect the merger between the Company and Yarrow Bioscience Operating Company Corp. (formerly known as Yarrow Bioscience, Inc.).
The preceding information is filed hereunder as Exhibit 99.2,
which is incorporated herein by reference.
All revisions to the Annual Report relate solely to the item set forth
above. These revisions have no effect on the Company’s previously reported results of operations, financial position, or cash flows.
The information in this Current Report on Form 8-K should be read in conjunction with the Annual Report (except for the items revised
herein), which was previously filed with the Securities and Exchange Commission (the “SEC”). All other information in the
Annual Report remains unchanged and the items in the Annual Report have not been updated for events occurring after December 31,
2025, except as expressly set forth in Exhibit 99.2. For significant developments since December 31, 2025, refer to subsequently
filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
The information in this Current Report on Form 8-K is deemed incorporated
by reference into the Company’s registration statements filed under the Securities Act of 1933, as amended (the “Securities
Act”).
Filed exhibits (2)
EX-99.1 2 tm2624937d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 1 Bringing life into balance Yarrow Bioscience Overview September 2026 2 Disclaimers The information contained in this presentation has been prepared by Yarrow Bioscience, Inc. and its affiliates (“Yarrow” or t he “Company”) and contains information pertaining to the business and operations of the Company. The information contained in this presentation: (a) is provided as of the date hereof, is subject to change without notice, and is based on publicly avail abl e information, internally developed data as well as third - party information from other sources; (b) does not purport to contain all the information that may be necessary or desirable to fully and accurately evaluate an investment in the Company; (c) is not to b e c onsidered as a recommendation by the Company that any person make an investment in the Company; and (d) is for information purposes only and shall not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an o ffe r to buy, sell or issue, or subscribe for any securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful. Where …
Open exhibit ↗EX-99.2 3 tm2624937d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 PART I, ITEM 1. BUSINESS Overview Yarrow Bioscience, Inc. (“Yarrow”) is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. Yarrow’s lead product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor (“TSHR”), which Yarrow plans to develop for the treatment of Graves’ disease (“GD”) and thyroid eye disease (“TED”). Both GD and TED are serious and poorly treated autoimmune diseases in which autoantibodies against TSHR attack and overstimulate the receptor, leading to a wide spectrum of thyroidal and extra-thyroidal clinical sequelae. YB-101 was designed to selectively bind to TSHR and block autoantibody-induced receptor activation, thereby directly inhibiting the pathogenic activity of thyroid-stimulating autoantibodies that drive disease progression in GD and TED as well as the biological pathway responsible for hyperthyroidism and orbitopathy. Yarrow believes that this novel and targeted approach represents a potential breakthrough for patients with GD and TED and has the …
Open exhibit ↗